NCT00962936View on ClinicalTrials.gov

Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

October 31, 2011

Study Completion Date

January 31, 2013

Conditions
Chronic Hepatitis C
Interventions
DRUG

CT-011

CT-011

Trial Locations (1)

91120

Hadassah Medical Center, Jerusalem

Sponsors

Lead Sponsor

CureTech Ltd
All Listed Sponsors
collaborator

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

lead

CureTech Ltd

INDUSTRY